

«ClientName»
«ClientAdd1»
«ClientAdd2»
«ClientAdd3»
«ClientAdd4»
«ClientAdd5»
«ClientPC»
«ClientCountry»

Financial Adviser

«AgentName»
«AgentAdd1»
«AgentAdd2»
«AgentAdd3»
«AgentAdd4»
«AgentAdd5»
«AgentPC»
«AgentCountry»

September 2025

**THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.
IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE.**

Friends Provident International Limited (“FPIL”) is responsible for the information contained in this notice. To the best of the knowledge and belief of FPIL (having taken all reasonable care to ensure that such is the case), the information contained in this notice is, at the date of this letter, in accordance with the facts and there are no other facts the omission of which would make any statement in this notice misleading. FPIL accepts responsibility accordingly for the information contained in this notification.

Dear Policyholder

**Policy Number: «Policy_No»
Your financial adviser: «AgentName»
Region designation: Hong Kong Onshore policyholder**

Re: Elite, Executive Savings Plan, Flexible Growth Plan, International Investment Account, International Pension Plan, International Portfolio Bond, International Savings Plan, Managed Portfolio Account, Premier, Premier II, Premier Investment Plan, Premier Ultra, Reserve, Summit, Summit II and Zenith (collectively, the “Schemes”)

Notification of changes to the underlying funds of:

**Franklin Biotechnology Discovery (H28) (the “Affected Investment-linked Fund 1”)
Franklin Mutual European (H89) (the “Affected Investment-linked Fund 2”)
(together the “Affected ILFs”)**

We are writing to you as your policy holds units in one or more of the FPIL Affected ILFs named above. We have been notified by Franklin Templeton Investments (Asia) Limited (the “Company”) of its changes to the Environmental, Social and Governance (“ESG”) exclusions in the SFDR pre-contractual disclosures. This change took effect **22 September 2025 (the “Effective Date”)**

Changes to the ESG exclusions in the SFDR pre-contractual disclosures

The Company has informed us that it made amendments to the SFDR pre-contractual disclosures of the underlying funds of the Affected ILFs on the Effective Date. These changes are to the paragraph under the section titled ‘*What investment strategy does this financial product follow?*’. The ESG exclusions in the SFDR pre-contractual disclosures will be revised as follows to the underlying funds and accordingly to our Affected ILFs:

Affected ILF fund name	Summary of change(s)
Franklin Biotechnology Discovery (H28)	<p>Removal of the following exclusion:</p> <ul style="list-style-type: none"> <i>Generate more than 10% of revenue from the production and/or distribution of weapons;</i> <p>Update to the following exclusion:</p> <ul style="list-style-type: none"> <i>Manufacture tobacco or tobacco products; or those that derive more than 5% of their revenue from such products;</i>
Franklin Mutual European (H89)	<p>Removal of the following exclusion:</p> <ul style="list-style-type: none"> <i>Derive more than 10% of revenue from the manufacture or sale of weapons;</i>

These changes will happen automatically within your policy or contract and you do not need to take any action.

Should you wish to switch your existing investment out of the Affected ILFs, or to redirect future regular premiums (if any) to a different investment-linked fund, you are free to do so, without charge, by completing the Switch/Redirection instruction form and returning it to our Hong Kong office, a copy of which is available on request.

Please note that you can also switch your investment-linked funds or redirect future premiums at any time, online through the FPI Portal, without charge. Simply log in at <https://portal.fpiinternational.com>. It is a simple, convenient and secure way to manage your policy.

You should read the corresponding offering documents (including Product Key Facts Statement) of the underlying funds (including, without limitation, their investment objectives and policies, risk factors and charges), which will be made available by our Hong Kong office upon request.

We recommend that you seek the advice of your usual independent financial adviser before making any investment decisions.

If you have any questions regarding your policy or the investment-linked funds in which you are invested, please contact our Hong Kong office:

Friends Provident International
803, 8/F, One Kowloon
1 Wang Yuen Street, Kowloon Bay
Hong Kong

Tel: +852 3550 6188
Fax: +852 2868 4983
Email: customerservicing@fpihk.com

Investment-linked fund prices may fluctuate and are not guaranteed. Investment involves risk. Past performance should not be viewed as a reliable guide of future performance.

Please refer to the offering documents of the Schemes for further details.

Yours sincerely



Chris Corkish
Head of Investment Marketing

«ClientName»
«ClientAdd1»
«ClientAdd2»
«ClientAdd3»
«ClientAdd4»
«ClientAdd5»
«ClientPC»
«ClientCountry»

財務顧問

«AgentName»
«AgentAdd1»
«AgentAdd2»
«AgentAdd3»
«AgentAdd4»
«AgentAdd5»
«AgentPC»
«AgentCountry»

2025 年 9 月

本項為重要文件，請即時查閱。
如有疑問，請尋求專業意見。

英國友誠國際有限公司（「FPIL」）對本通知所載資訊負責。據 FPIL 所知及所信（已採取一切合理謹慎措施確保情況屬實），本通知所載資訊在本函發出之日均與事實相符，且無任何其他遺漏會使本通知中任何陳述產生誤導。FPIL 對本通知所載資訊承擔相應責任。

致保單持有人

保單編號：«Policy_No»
閣下的財務顧問：«AgentName»
指定地區：香港境內保單持有人

關於：萬全精英投資計劃、行政人員儲蓄計劃、靈活增長計劃、萬全國際投資計劃、International Pension Plan、全能投資組合計劃、International Savings Plan、Managed Portfolio Account、優裕計劃、曉逸投資相連壽險計劃、Premier Investment Plan、卓裕計劃、豐裕計劃、嶺豐投資計劃、嶺豐投資相連壽險計劃 II 及萬全智富投資計劃（一併稱為「計劃」）

關於以下相關基金變更之通知：

富蘭克林生物科技新領域基金 (H28)（「受影響之投資相連基金 1」）
富蘭克林互惠歐洲基金 (H89)（「受影響之投資相連基金 2」）
（合併稱為「受影響之投資相連基金」）

我們現致函閣下乃閣下持有上述一或多個 FPIL 受影響之投資相連基金的單位。我們接獲富蘭克林鄧普頓投資（亞洲）有限公司（「該公司」）通知，其已修訂 SFDR 合約前披露文件中有關環境、社會及管治（「ESG」）的排除條件。該修訂於 **2025 年 9 月 22 日**（「生效日期」）生效

SFDR 合約前披露中 ESG 排除條件的變更

該公司已告知我們，其已於生效日期，對受影響之投資相連基金的相關基金之 SFDR 合約前披露文件作出修訂。此等修訂涉及題為「**此金融產品遵循什麼投資策略？**」之章節下的段落。相關基金於 SFDR 之合約前披露文件內有關 ESG 的排除條件，將作以下修訂，並因此適用於我們的受影響之投資相連基金：

受影響之投資相連基金的名稱	變更摘要
富蘭克林生物科技新領域基金 (H28)	刪除下列排除條件： <ul style="list-style-type: none"> 從生產和/或分銷武器產生超過 10% 的收入； 更新至下列排除條件： <ul style="list-style-type: none"> 生產煙草或煙草產品；或其超過 5% 的收入來自等產品；
富蘭克林互惠歐洲基金 (H89)	刪除下列排除條件： <ul style="list-style-type: none"> 從製造或銷售武器獲得超過 10% 的收入；

這些變更將在閣下的保單或合約中自動執行，閣下無須採取任何行動。

閣下可隨時將現有的投資從受影響之投資相連基金免費轉換至另一投資相連基金，或將日後的定期保費（如適用）轉換至閣下保單下的另一投資相連基金，費用全免。閣下可向本公司索取基金轉移／重新調配指示表格，並將填妥的表格交回我們的香港辦事處。

請注意，閣下也可以隨時透過 FPI 網站以線上方式免費轉換閣下的投資相連基金或重新調配未來的保費。閣下只需登入網上系統 <https://portal.fpinternational.com> 即可。這是一種簡單、方便和安全的管理保單的方法。

閣下應閱讀相關基金的相應銷售文件（包括產品資料概要），當中包括但不限於其投資目標及政策、風險因素及收費。我們的香港辦事處將因應要求提供該等資料。

我們建議閣下在作出任何投資決定之前，向閣下的常用獨立財務顧問尋求意見。

倘若閣下對閣下的保單或投資的投資相連基金有任何疑問，請聯絡香港辦事處：

英國友誠國際有限公司
一號九龍 8 樓 803 室
九龍灣宏遠街 1 號
香港

電話：+852 3550 6188
傳真：+852 2868 4983
電郵：customerservicing@fpink.com

投資相連基金的價格可能出現波動，並且無法保證。投資涉及風險。往績未必能作為日後表現的指標。

更多詳情請參閱計劃的銷售文件。

謹啟



Chris Corkish
投資行銷部主管